Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA and DNA-associated enzymes in Trypanosoma species represent a critical class of therapeutic targets due to the unique structural organization of the parasite's genome, particularly the kinetoplast DNA (kDNA) (Shapiro & Englund, 1995). The kDNA is a massive network of catenated circular DNA molecules, consisting of maxicircles and minicircles, located within the parasite's single large mitochondrion. Specialized enzymes, including DNA topoisomerases, polymerases, and ligases, are essential for the replication, decatenation, and maintenance of this complex genetic architecture (Darsley et al., 2007). Therapeutic agents such as pentamidine and diminazene target these systems by binding to the DNA minor groove or interfering with enzymatic functions, leading to the rapid loss of kDNA and parasite death (Werbovetz, 2006). Because the replication machinery and structural organization of kDNA are distinct from host nuclear and mitochondrial DNA processes, they provide a basis for selective chemotherapy against trypanosomal infections. These targets are central to the treatment of Human African Trypanosomiasis (sleeping sickness) and American Trypanosomiasis (Chagas disease) (Nguewa et al., 2004).
The mechanism of action involves the disruption of DNA integrity and function through various pathways. Diamidines like pentamidine and diminazene bind to the minor groove of AT-rich regions in kinetoplast DNA, interfering with replication and transcription (Werbovetz, 2006). Other agents inhibit DNA-associated enzymes such as Topoisomerase II, which is essential for the decatenation of the linked DNA circles in the kinetoplast, leading to lethal DNA damage and cell cycle arrest (Shapiro & Englund, 1995). Nitro-compounds like benznidazole and nifurtimox act by undergoing reductive activation to form reactive intermediates that cause oxidative damage and strand breaks in the parasite's DNA (Wilkinson et al., 2008).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA and DNA-associated enzymes (Trypanosoma).